It has also been reported that CCL2/MCP-1 is increased after paclitaxel–carboplatin combination treatment, resulting in macrophage recruitment into ovarian tumors and inhibition of CCL2/MCP-1 increases response to chemotherapy (47, 48). The gene discussed is CCL2; the disease is ovarian neoplasm.